CXCR3 and colitis: Blockade of the CXCL10-CXCR3 axis with monoclonal anti-CXCL10 antibodies ameliorates colitis in IL-10−/− mice by decreasing infiltrating T cells[25], and confers protection from DSS-induced colitis[23].